Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

<p>Table S8. Genes used for gene set analysis</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Sung-Eun Lee (14855067) (author)
Drugi avtorji:	Feng Wang (14855070) (author), Maison Grefe (14855073) (author), Abel Trujillo-Ocampo (14855076) (author), Wilfredo Ruiz-Vasquez (14855079) (author), Koichi Takahashi (14855082) (author), Hussein A. Abbas (14855085) (author), Pamella Borges (14855088) (author), Dinler Amaral Antunes (14855091) (author), Gheath Al-Atrash (14855094) (author), Naval Daver (14855097) (author), Jeffrey J. Molldrem (14855100) (author), Andrew Futreal (14855103) (author), Guillermo Garcia-Manero (14855106) (author), Jin S. Im (14855109) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Immuno-oncology Hematological Cancers Immunotherapy Checkpoint blockade Tumor Microenvironment Tumor microcirculation
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
od: Dong-Chun Hong (16374308)
Izdano: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Izdano: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Izdano: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Izdano: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Izdano: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Izdano: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Izdano: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_l2aca1p6v1cf0kahugahr2f542